Cargando…

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer

BACKGROUND: To evaluate the relationship between body composition and the oncological outcome of androgen deprivation therapy (ADT), we investigated whether body composition features including the psoas muscle may be predictive factors of ADT. METHODS: This study enrolled patients with hormone-naïve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwagi, Eiji, Shiota, Masaki, Masaoka, Hiroyuki, Imada, Kenjiro, Monji, Keisuke, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, Eto, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125377/
https://www.ncbi.nlm.nih.gov/pubmed/32257974
http://dx.doi.org/10.1016/j.prnil.2019.11.002
_version_ 1783515931868135424
author Kashiwagi, Eiji
Shiota, Masaki
Masaoka, Hiroyuki
Imada, Kenjiro
Monji, Keisuke
Takeuchi, Ario
Inokuchi, Junichi
Tatsugami, Katsunori
Eto, Masatoshi
author_facet Kashiwagi, Eiji
Shiota, Masaki
Masaoka, Hiroyuki
Imada, Kenjiro
Monji, Keisuke
Takeuchi, Ario
Inokuchi, Junichi
Tatsugami, Katsunori
Eto, Masatoshi
author_sort Kashiwagi, Eiji
collection PubMed
description BACKGROUND: To evaluate the relationship between body composition and the oncological outcome of androgen deprivation therapy (ADT), we investigated whether body composition features including the psoas muscle may be predictive factors of ADT. METHODS: This study enrolled patients with hormone-naïve metastatic prostate cancer who were treated with primary ADT from April 1996 to November 2013 at Kyushu University Hospital and who underwent a computed tomography scan before primary ADT for calculating body fat percentage, psoas muscle ratio (psoas muscle, cm(3)/height, cm), and body mass index. RESULTS: Of the 178 patients enrolled, 60 patients died during follow-up. Median follow-up was 32 months, and progression-free survival and overall survival (OS) were 28 and 80 months, respectively. Multivariate analysis revealed that the psoas muscle ratio was correlated with OS (hazard ratio: 0.448; 95% confidence interval = 0.206–0.922; p = 0.028). CONCLUSIONS: This study demonstrated that higher psoas muscle ratio predicts longer OS among patients with nonlocalized prostate cancer treated with primary ADT.
format Online
Article
Text
id pubmed-7125377
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Asian Pacific Prostate Society
record_format MEDLINE/PubMed
spelling pubmed-71253772020-04-06 Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer Kashiwagi, Eiji Shiota, Masaki Masaoka, Hiroyuki Imada, Kenjiro Monji, Keisuke Takeuchi, Ario Inokuchi, Junichi Tatsugami, Katsunori Eto, Masatoshi Prostate Int Original Article BACKGROUND: To evaluate the relationship between body composition and the oncological outcome of androgen deprivation therapy (ADT), we investigated whether body composition features including the psoas muscle may be predictive factors of ADT. METHODS: This study enrolled patients with hormone-naïve metastatic prostate cancer who were treated with primary ADT from April 1996 to November 2013 at Kyushu University Hospital and who underwent a computed tomography scan before primary ADT for calculating body fat percentage, psoas muscle ratio (psoas muscle, cm(3)/height, cm), and body mass index. RESULTS: Of the 178 patients enrolled, 60 patients died during follow-up. Median follow-up was 32 months, and progression-free survival and overall survival (OS) were 28 and 80 months, respectively. Multivariate analysis revealed that the psoas muscle ratio was correlated with OS (hazard ratio: 0.448; 95% confidence interval = 0.206–0.922; p = 0.028). CONCLUSIONS: This study demonstrated that higher psoas muscle ratio predicts longer OS among patients with nonlocalized prostate cancer treated with primary ADT. Asian Pacific Prostate Society 2020-03 2019-11-30 /pmc/articles/PMC7125377/ /pubmed/32257974 http://dx.doi.org/10.1016/j.prnil.2019.11.002 Text en © 2019 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Kashiwagi, Eiji
Shiota, Masaki
Masaoka, Hiroyuki
Imada, Kenjiro
Monji, Keisuke
Takeuchi, Ario
Inokuchi, Junichi
Tatsugami, Katsunori
Eto, Masatoshi
Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
title Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
title_full Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
title_fullStr Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
title_full_unstemmed Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
title_short Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
title_sort relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125377/
https://www.ncbi.nlm.nih.gov/pubmed/32257974
http://dx.doi.org/10.1016/j.prnil.2019.11.002
work_keys_str_mv AT kashiwagieiji relationshipbetweenbodycompositionandhormonesensitivityforandrogendeprivationtherapyinpatientswithmetastaticprostatecancer
AT shiotamasaki relationshipbetweenbodycompositionandhormonesensitivityforandrogendeprivationtherapyinpatientswithmetastaticprostatecancer
AT masaokahiroyuki relationshipbetweenbodycompositionandhormonesensitivityforandrogendeprivationtherapyinpatientswithmetastaticprostatecancer
AT imadakenjiro relationshipbetweenbodycompositionandhormonesensitivityforandrogendeprivationtherapyinpatientswithmetastaticprostatecancer
AT monjikeisuke relationshipbetweenbodycompositionandhormonesensitivityforandrogendeprivationtherapyinpatientswithmetastaticprostatecancer
AT takeuchiario relationshipbetweenbodycompositionandhormonesensitivityforandrogendeprivationtherapyinpatientswithmetastaticprostatecancer
AT inokuchijunichi relationshipbetweenbodycompositionandhormonesensitivityforandrogendeprivationtherapyinpatientswithmetastaticprostatecancer
AT tatsugamikatsunori relationshipbetweenbodycompositionandhormonesensitivityforandrogendeprivationtherapyinpatientswithmetastaticprostatecancer
AT etomasatoshi relationshipbetweenbodycompositionandhormonesensitivityforandrogendeprivationtherapyinpatientswithmetastaticprostatecancer